Breaking News Instant updates and real-time market news.

DBVT

DBV Technologies

$10.22

0.595 (6.18%)

, AIMT

Aimmune

$24.66

(0.00%)

17:57
09/13/19
09/13
17:57
09/13/19
17:57

DBV Technologies falls 2% after FDA panel votes in favor of Aimmune drug

DBVT

DBV Technologies

$10.22

0.595 (6.18%)

AIMT

Aimmune

$24.66

(0.00%)

  • 13

    Sep

DBVT DBV Technologies
$10.22

0.595 (6.18%)

06/17/19
06/17/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. DBV Technologies (DBVT) initiated with a Buy at Goldman Sachs. 2. Amicus (FOLD) initiated with a Buy at H.C. Wainwright. 3. Viper Energy (VNOM) initiated with a Buy at SunTrust. 4. GNC Holdings (GNC) initiated with a Hold at Jefferies. 5. Eventbrite (EB) initiated with an Outperform at William Blair. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/12/19
WEDB
07/12/19
NO CHANGE
Target $79
WEDB
Outperform
Aimmune selloff on ICER report overdone, says Wedbush
Wedbush analyst Liana Moussatos views the selloff yesterday in shares of Aimmune Therapeutics as overdone. The Institute for Clinical and Economic Review on Wednesday released a final report on emerging desensitization treatments for peanut allergy and compared the clinical effectiveness and value of Aimmune's AR101, DBV Technologies' (DBVT) Viaskin and non-commercialized oral immunotherapy for treatment of peanut allergy, Moussatos tells investors in a research note. However, the ICER report excluded long-term desensitization and patient quality-of-life results for AR101 and hence failed to recognize the full value of AR101 immunotherapy for peanut allergy, says the analyst. She sees an "excellent entry point" into Aimmune shares following yesterday's selloff and reiterates an Outperform rating on the name wih a $79 price target.
08/05/19
HCWC
08/05/19
NO CHANGE
Target $25
HCWC
Buy
H.C. Wainwright reiterates Buy on DBV ahead of expected BLA resubmission
H.C. Wainwright analyst Andrew Fein says that as DBV Technologie (DBVT) moves forward towards an anticipated Biologics License Application resubmission for Viaskin Peanut in Q3, he continues to be supportive of the overall value, safety, and efficacy of the Viaskin Peanut program. Following organizational updates, a "straightforward BLA resubmission could refresh investors' confidence in management, while addressing the regulatory overhang," Fein tells investors in a research note. He reiterates a Buy rating on DBV shares with a $25 price target. His confidence in the Viaskin Peanut program has been based on "exceptional safety and sufficient efficacy to manage the risk of accidental exposure." The analyst believes these properties differentiate Viaskin Peanut from the peanut oral immunotherapy being developed by Aimmune (AIMT).
09/12/19
LEER
09/12/19
NO CHANGE
LEER
Outperform
Aimmune Palforzia safety bodes well for DBV'S Viaskin Peanut, says SVB Leerink
SVB Leerink analyst Joseph Schwartz notes that FDA's Allergenic Products Advisory Committee released briefing documents pertaining to its upcoming AdCom panel discussion for Aimmune's (AIMT) Palforzia on Friday. Because efficacy has been robust for Palforzia, the analyst thinks investors will be acutely focused on safety, and believes the details surrounding Palforzia safety bode well for DBV Technologies' (DBVT) Viaskin Peanut as it could provide a convenient and safer alternative for peanut allergic patients. Despite slower onset of efficacy, Viaskin Peanut's favorable safety profile could promote longer-term use which previously has been shown to continue to improve on efficacy, he contends. Schwartz has an Outperform rating on DBV Technologies' shares.
AIMT Aimmune
$24.66

(0.00%)

09/11/19
STFL
09/11/19
NO CHANGE
STFL
Hold
Aimmune briefing docs look 'pretty benign,' says Stifel
After the FDA posted briefing documents ahead of its Allergenic Products Advisory Committee Meeting on September 13 to review Aimmune Therapeutics' peanut allergen powder, Palforzia, Stifel analyst Derek Archila said the documents "seem pretty benign" and did not generate any new issues. He expects the focus of the Adcom to be on safety, which is not "new" news, and thinks the document release should provide some relief for shares given that the "worst case" scenario in terms of the panel may be off the table. He sees the risk/reward as less favorable once Palforzia is approved given the commercial/logistical challenges he sees ahead, added Archila, who keeps a Hold rating on Aimmune shares.
09/11/19
PIPR
09/11/19
NO CHANGE
Target $60
PIPR
Overweight
Piper says FDA briefing docs remove key underpinning of Aimmune bear thesis
Piper Jaffray analyst Christopher Raymond said the FDA's briefing documents for its upcoming panel review of AR101, now called Palforzia, are "benign, even surprisingly positive," and he feels even more confident about the chances for approval of Aimmune's peanut allergy treatment. A key point in the documents is that the FDA is directing the panel to look at reactions to accidental exposures as perhaps a better predictor of real world utility than a double blinded placebo controlled food challenge, said Raymond, who contends that this "singular statement...removes a key underpinning from the bear thesis which points to the imbalance of systemic allergic reactions." The analyst, who anticipates a 2020 approval and revenue of over $1.5B by 2025, keeps an Overweight rating and $60 price target on Aimmune shares.
09/13/19
PIPR
09/13/19
NO CHANGE
PIPR
Aimmune's AR101 prospects derisked by FDA panel decision, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond kept an Overweight rating and $60 price target on Aimmune after an FDA's Allergenic Products Advisory Committee, or APAC, voted in favor of the company's AR101 peanut allergy drug on both efficacy and safety. The analyst said, after the vote, he "increasingly likes the chances for Palforzia approval by late January 2020 (if not sooner)." Raymond noted that the stock is likely to open sharply higher on Monday as there is a 30% short interest in Aimmune, and said he is a buyer on the open as he sees "a lot of room to go."

TODAY'S FREE FLY STORIES

03:15
10/21/19
10/21
03:15
10/21/19
03:15
General news
FX Action: USD-CAD posted a fresh two-and-a-half-month low »

FX Action: USD-CAD posted…

03:00
10/21/19
10/21
03:00
10/21/19
03:00
General news
Asian Market Update: »

Asian Market Update: It…

EDPFY

Energias de Portugal

$0.00

(0.00%)

19:56
10/20/19
10/20
19:56
10/20/19
19:56
Upgrade
Energias de Portugal rating change at JPMorgan »

Energias de Portugal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

ARWR

Arrowhead

$35.98

-0.63 (-1.72%)

19:54
10/20/19
10/20
19:54
10/20/19
19:54
Recommendations
Arrowhead analyst commentary at Piper Jaffray »

Arrowhead price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$344.09

-25.04 (-6.78%)

, FB

Facebook

$185.96

-4.435 (-2.33%)

19:31
10/20/19
10/20
19:31
10/20/19
19:31
Hot Stocks
Fly Intel: Top five weekend stock stories »

Catch up on the…

BA

Boeing

$344.09

-25.04 (-6.78%)

FB

Facebook

$185.96

-4.435 (-2.33%)

T

AT&T

$38.46

0.64 (1.69%)

CMCSA

Comcast

$45.58

-0.36 (-0.78%)

CMCSK

Comcast

$0.00

(0.00%)

DIS

Disney

$130.91

-1.46 (-1.10%)

NFLX

Netflix

$275.40

-17.88 (-6.10%)

AMZN

Amazon.com

$1,757.77

-30.07 (-1.68%)

COP

ConocoPhillips

$53.99

-0.55 (-1.01%)

GMVHF

GVC Holdings

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 07

    Nov

  • 18

    Nov

  • 19

    Nov

  • 19

    Nov

  • 21

    Nov

CPTA

Capitala Finance

$9.11

0.13 (1.45%)

19:23
10/20/19
10/20
19:23
10/20/19
19:23
Downgrade
Capitala Finance rating change at Keefe Bruyette »

Capitala downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

GM

General Motors

$36.19

-0.01 (-0.03%)

, F

Ford

$9.29

0.18 (1.98%)

19:13
10/20/19
10/20
19:13
10/20/19
19:13
Periodicals
GM contract terms may be hard for rivals, NY Times says »

General Motors (GM) made…

GM

General Motors

$36.19

-0.01 (-0.03%)

F

Ford

$9.29

0.18 (1.98%)

FCAU

Fiat Chrysler

$13.22

0.085 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 29

    Oct

TRI

Thomson Reuters

$66.73

-0.08 (-0.12%)

19:09
10/20/19
10/20
19:09
10/20/19
19:09
Hot Stocks
Thomson Reuters issues statement on CEO succession planning »

Thomson Reuters has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

T

AT&T

$38.46

0.64 (1.69%)

, CMCSA

Comcast

$45.58

-0.36 (-0.78%)

16:45
10/20/19
10/20
16:45
10/20/19
16:45
On The Fly
Box Office Battle: 'Maleficent 2' wins weekend with just $36M »

"Box Office Battle" is…

T

AT&T

$38.46

0.64 (1.69%)

CMCSA

Comcast

$45.58

-0.36 (-0.78%)

CMCSK

Comcast

$0.00

(0.00%)

SNE

Sony

$59.23

-0.83 (-1.38%)

LGF.A

Lionsgate

$8.47

-0.13 (-1.51%)

LGF.B

Lionsgate

$7.96

-0.11 (-1.36%)

DIS

Disney

$130.91

-1.46 (-1.10%)

VIAB

Viacom

$22.05

-0.56 (-2.48%)

VIA

Viacom

$24.80

-0.8 (-3.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 07

    Nov

  • 07

    Nov

  • 07

    Nov

  • 14

    Nov

  • 14

    Nov

  • 18

    Nov

  • 19

    Nov

FB

Facebook

$185.96

-4.435 (-2.33%)

16:16
10/20/19
10/20
16:16
10/20/19
16:16
Periodicals
Facebook open to currency-pegged stablecoins, Reuters reports »

Facebook, facing growing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 27

    Oct

  • 30

    Oct

WYNN

Wynn Resorts

$113.55

-0.49 (-0.43%)

16:12
10/20/19
10/20
16:12
10/20/19
16:12
Periodicals
Ex-Wynn Resorts worker claims company spied on him, WSJ reports »

A former Wynn Resorts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SFTBY

SoftBank

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

16:01
10/20/19
10/20
16:01
10/20/19
16:01
Periodicals
SoftBank seeking to avoid WeWork's liabilities with new investment, Reuters says »

SoftBank (SFTBY) is…

SFTBY

SoftBank

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

JPM

JPMorgan

$120.60

0.21 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 04

    Nov

  • 06

    Nov

  • 21

    Nov

  • 14

    Jan

GM

General Motors

$36.19

-0.01 (-0.03%)

15:53
10/20/19
10/20
15:53
10/20/19
15:53
Periodicals
GM strike continues, pain felt by Midwest workers deepens, WSJ says »

With the strike at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

BA

Boeing

$344.09

-25.04 (-6.78%)

15:43
10/20/19
10/20
15:43
10/20/19
15:43
Periodicals
Boeing expresses regret over ex-pilot's 737 Max messages, Reuters says »

Boeing said that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

ED

Consolidated Edison

$91.54

0.22 (0.24%)

, MA

MasterCard

$270.90

-5.74 (-2.07%)

15:38
10/20/19
10/20
15:38
10/20/19
15:38
Hot Stocks
MasterCard expands Bill Pay Exchange partners »

Mastercard (MA) has…

ED

Consolidated Edison

$91.54

0.22 (0.24%)

MA

MasterCard

$270.90

-5.74 (-2.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 29

    Oct

  • 29

    Oct

  • 10

    Nov

  • 10

    Nov

  • 12

    Nov

LAZ

Lazard

$37.09

0.06 (0.16%)

15:33
10/20/19
10/20
15:33
10/20/19
15:33
Hot Stocks
Lazard announces resignation of Deputy CEO of Financial Advisory »

Lazard announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

  • 07

    Nov

  • 07

    Nov

ALXN

Alexion

$98.41

-1.53 (-1.53%)

15:25
10/20/19
10/20
15:25
10/20/19
15:25
Hot Stocks
Alexion ULTOMIRIS receives FDA approval for Atypical Hemolytic Uremic Syndrome »

Alexion Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 04

    Nov

  • 07

    Dec

BRBR

BellRing Brands

$16.65

-0.04 (-0.24%)

, POST

Post Holdings

$100.65

-0.8 (-0.79%)

09:49
10/20/19
10/20
09:49
10/20/19
09:49
On The Fly
Opening Day: BellRing climbs after $480M IPO »

BellRing Brands (BRBR)…

BRBR

BellRing Brands

$16.65

-0.04 (-0.24%)

POST

Post Holdings

$100.65

-0.8 (-0.79%)

IPHA

Innate Pharma

$6.05

0.19 (3.24%)

KRAT

Karat Packaging

$0.00

(0.00%)

ONEW

OneWater Marine

$0.00

(0.00%)

BRP

BRP Group

$0.00

(0.00%)

PGNY

Progyny

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Oct

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 07

    Dec

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

BA

Boeing

$344.09

-25.04 (-6.78%)

08:31
10/19/19
10/19
08:31
10/19/19
08:31
Periodicals
Boeing recovery getting 'a lot more complicated,' Barron's says »

Boeing shares fell on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

GMVHF

GVC Holdings

$0.00

(0.00%)

08:27
10/19/19
10/19
08:27
10/19/19
08:27
Periodicals
GVC Holdings looking like 'a good bet,' Barron's says »

GVC Holdings' stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EYE

National Vision

$22.98

-0.94 (-3.93%)

08:19
10/19/19
10/19
08:19
10/19/19
08:19
Periodicals
Street sees National Vision as a buy, some shorts disagree, Barron's says »

National Vision has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CI

Cigna

$167.11

2.3 (1.40%)

, HUM

Humana

$289.59

4 (1.40%)

08:13
10/19/19
10/19
08:13
10/19/19
08:13
Periodicals
Healthcare stocks getting 'back on their feet,' Barron's says »

The sector is the second…

CI

Cigna

$167.11

2.3 (1.40%)

HUM

Humana

$289.59

4 (1.40%)

UNH

UnitedHealth

$245.59

1.84 (0.75%)

WCG

WellCare

$274.54

0.09 (0.03%)

HNT

Health Net

$0.00

(0.00%)

MOH

Molina Healthcare

$123.03

1.47 (1.21%)

TEVA

Teva

$7.50

-0.26 (-3.35%)

AZN

AstraZeneca

$43.86

-0.25 (-0.57%)

BMY

Bristol-Myers

$53.02

0.6 (1.14%)

LLY

Eli Lilly

$108.68

0.24 (0.22%)

GSK

GlaxoSmithKline

$42.52

0.04 (0.09%)

JNJ

Johnson & Johnson

$127.73

-8.47 (-6.22%)

MRK

Merck

$84.68

0.88 (1.05%)

NVS

Novartis

$86.86

-0.395 (-0.45%)

PFE

Pfizer

$36.46

(0.00%)

RHHBY

Roche

$0.00

(0.00%)

SNY

Sanofi

$46.13

-0.43 (-0.92%)

ANTM

Anthem

$249.55

0.3 (0.12%)

CVS

CVS Health

$66.17

-0.31 (-0.47%)

CNC

Centene

$46.92

-0.28 (-0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 31

    Oct

  • 31

    Oct

  • 31

    Oct

  • 04

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 07

    Nov

  • 08

    Nov

  • 13

    Nov

  • 14

    Nov

  • 18

    Nov

  • 07

    Dec

  • 24

    Jan

  • 24

    Jan

  • 14

    Mar

COP

ConocoPhillips

$53.99

-0.55 (-1.01%)

08:03
10/19/19
10/19
08:03
10/19/19
08:03
Periodicals
ConocoPhillips stock looking cheap following selloff, Barron's says »

At a time when Wall…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 19

    Nov

AMZN

Amazon.com

$1,757.77

-30.07 (-1.68%)

, NFLX

Netflix

$275.40

-17.88 (-6.10%)

08:00
10/19/19
10/19
08:00
10/19/19
08:00
Periodicals
Comcast stacking up better than investors might expect, Barron's says »

If cord-cutting…

AMZN

Amazon.com

$1,757.77

-30.07 (-1.68%)

NFLX

Netflix

$275.40

-17.88 (-6.10%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$45.58

-0.36 (-0.78%)

T

AT&T

$38.46

0.64 (1.69%)

DIS

Disney

$130.91

-1.46 (-1.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 29

    Oct

  • 07

    Nov

  • 18

    Nov

  • 19

    Nov

  • 21

    Nov

AKS

AK Steel

$2.45

0.055 (2.30%)

, MT

ArcelorMittal

$14.58

0.03 (0.21%)

07:41
10/19/19
10/19
07:41
10/19/19
07:41
On The Fly
Week in Review: How Trump's policies moved stocks »

Catch up on the top…

AKS

AK Steel

$2.45

0.055 (2.30%)

MT

ArcelorMittal

$14.58

0.03 (0.21%)

NUE

Nucor

$51.69

-0.11 (-0.21%)

STLD

Steel Dynamics

$28.71

-0.04 (-0.14%)

TMST

TimkenSteel

$5.42

-0.015 (-0.28%)

X

U.S. Steel

$10.72

0.1 (0.94%)

GM

General Motors

$36.19

-0.01 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Oct

  • 31

    Oct

  • 01

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.